索磷布韦联合利巴韦林治疗慢性丙肝期间华法林需求量增加一例
报告一例63岁白人男性房颤合并心源性卒中史患者,长期华法林抗凝稳定在52.5 mg/周。接受索磷布韦400 mg每日口服联合按体重利巴韦林600 mg每日两次、共12周方案治疗HCV基因2型感染后,因INR低于治疗范围,华法林剂量逐步由52.5 mg/周增至77.5 mg/周。
要点
- HCV治疗启动后9天即出现首次华法林剂量上调,提示需早期监测INR。
- 12周治疗期间华法林由52.5 mg/周渐增至77.5 mg/周以维持治疗范围INR。
- 停用抗HCV方案后仍需较基线更高剂量华法林,至2016年6月维持62.5–65 mg/周。
核心结论
- 稳定剂量华法林患者在启动12周索磷布韦联合利巴韦林方案后INR下降,需增加华法林剂量以维持治疗范围。
研究设计与样本
- 单例病例报告:63岁白人男性,因房颤及心源性卒中史长期华法林抗凝,2014年9月起接受索磷布韦400 mg每日口服联合按体重利巴韦林600 mg每日两次、共12周,治疗HCV基因2型感染。
主要发现
- 治疗前华法林52.5 mg/周且INR在治疗范围,治疗启动后9天首次调整剂量。
- 12周治疗期间华法林由52.5 mg/周逐步增至77.5 mg/周。
- 抗HCV方案结束3周后INR为3.06,华法林减至70 mg/周。
- 抗HCV方案结束18周后INR为3.86,华法林减至65 mg/周;3周后INR为2.19并维持65 mg/周。
- 截至2016年6月仍需华法林62.5–65 mg/周维持治疗范围INR。
临床怎么用
- 丙肝患者接受索磷布韦联合利巴韦林治疗前后及期间应加强INR监测并据此调整华法林剂量。
局限性
- 为单例病例报告,不能确立因果关系,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A case of increased warfarin requirements during treatment with sofosbuvir and ribavirin for chronic hepatitis C virus (HCV) infection is reported. SUMMARY: A 63-year-old white man receiving long-term anticoagulation with warfarin for atrial fibrillation and a history of cardioembolic stroke was initiated in September 2014 on a 12-week course of sofosbuvir 400 mg orally daily and weight-based ribavirin 600 mg orally twice daily for HCV genotype 2 infection. Before starting this treatment regimen, the patient had been stable on warfarin 52.5 mg weekly, with therapeutic International Normalized Ratio (INR) values. During the 12-week course of sofosbuvir and ribavirin, the patient's dose of warfarin progressively increased from 52.5 to 77.5 mg weekly due to subtherapeutic INRs, with the first adjustment in the warfarin dose occurring 9 days after initiation of HCV treatment. Three weeks after completion of the sofosbuvir and ribavirin regimen, the patient's INR was 3.06, and his warfarin dose was then decreased to 70 mg weekly. The patient continued with this warfarin dosage until 18 weeks after completion of his HCV regimen. The dosage was then decreased to 65 mg weekly after an INR of 3.86. Three weeks later, his INR was 2.19, and warfarin 65 mg weekly was continued. As of June 2016, the patient has continued to require warfarin 62.5-65 mg weekly to maintain a therapeutic INR. CONCLUSION: A 63-year-old man on a stable dose of warfarin experienced a decrease in INR values after the initiation of a 12-week course of sofosbuvir and ribavirin for the treatment of chronic HCV infection.
引用
- Peterson D, Van Ermen A. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin. Am J Health Syst Pharm. 2017. PMID: 28596225. doi:10.2146/ajhp160730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。